<DOC>
	<DOCNO>NCT02461186</DOCNO>
	<brief_summary>Emerging resistance artemisinins partner drug severely threaten treatment falciparum malaria Myanmar artemisinin combination therapy . To inform drug policy , crucial evaluate alternative antimalarial treatment . The investigator propose randomized clinical trial compare parasite clearance parameter efficacy 3 day arterolane-piperaquine standard treatment 3 day dihydroartemisinin ( DHA ) -piperaquine adult patient uncomplicated falciparum malaria Myanmar stratify presence `` K13 '' mutation infect parasite strain .</brief_summary>
	<brief_title>Arterolane-PQP Versus DHA-PQP Uncomplicated Falciparum Malaria Eastern Myanmar</brief_title>
	<detailed_description>Primary Objective : - To assess parasite clearance half-life arterolane-piperaquine compare DHA-piperaquine patient artemisinin resistant uncomplicated falciparum malaria , define presence `` K13 '' mutation infect parasite strain . Secondary Objectives : - To assess therapeutic efficacy arterolane-piperaquine DHA-piperaquine treatment uncomplicated falciparum malaria mixed infection ( P.falciparum ( PF ) + non-falciparum specie ) Day 42 , stratify presence artemisinin resistance infect parasite strain . - To assess frequency adverse event serious adverse event arterolane-piperaquine compare DHA-piperaquine . - To assess efficacy parameter related parasite clearance parasite cure rate well gametocyte carriage . - To obtain pharmacokinetic ( PK ) pharmacokinetic/pharmacodynamics ( PK/PD ) data arterolane-piperaquine DHA-piperaquine .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Male female age ≥ 18 year old Symptomatic malaria infection , i.e . history fever presence fever &gt; 37.5°c ( tympanic ) within last 24 hour . Microscopic confirmation asexual stage P.falciparum ( may mix nonfalciparum specie ) parasitaemia &gt; 10,000 parasites/µL Able take oral medication Willingness ability patient comply study protocol duration study Written inform consent give participate trial Pregnancy lactation ( urine test β HCG perform woman child bear age 18 45 year old ) P.falciparum asexual stage parasitaemia great equal 4 % red blood cell ( 175,000/µL ) . Signs symptom indicative severe malaria : Impaired consciousness Severe anaemia ( Hct &lt; 15 % ) Bleeding disorder evidence epistaxis , bleed gum , frank haematuria , bleed venipuncture sit Respiratory distress Severe jaundice Have take full course DHApiperaquine , artemetherlumefantrin antimalarial treatment previous 42 day Known hypersensitivity artemisinins piperaquine defined history erythroderma/other severe cutaneous reaction angioedema History splenectomy History take medicinal product know prolong QTc interval , include : Antiarrhythmics ( e.g . amiodarone , disopyramide , dofetilide , ibutilide , procainamide , quinidine , hydroquinidine , sotalol ) . Neuroleptics ( e.g . phenothiazine , sertindole , sultopride , chlorpromazine , haloperidol , mesoridazine , pimozide , thioridazine ) , antidepressive agent . Certain antimicrobial agent , include agent follow class : macrolides ( e.g . erythromycin , clarithromycin ) , fluoroquinolones ( e.g . moxifloxacin , sparfloxacin ) , imidazole triazole antifungal agent , pentamidine saquinavir . The nonsedating antihistamine terfenadine , astemizole , mizolastine . Other drug : cisapride , droperidol , domperidone , bepridil , diphemanil , probucol , levomethadyl , methadone , vinca alkaloid , arsenic trioxide . History take drug know metabolise cytochrome enzyme CYP2D6 include flecainide , metoprol , imipramine , amitriptyline , clomipramine . Family history sudden unexplained death , personal family history predispose cardiac condition arrhythmia/QT prolongation ( include congenital long QT syndrome , arrhythmia , QTc interval great 450 millisecond either Bazett Fridericia correction ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Arterolane-piperaquine</keyword>
	<keyword>Dehydroartemisinin-piperaquine</keyword>
	<keyword>therapeutic efficacy</keyword>
	<keyword>Uncomplicated falciparum malaria</keyword>
	<keyword>Artemisinin-resistant</keyword>
</DOC>